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Background: Primary gastric adenosquamous carcinoma (ASC) is a rare subset of ASC. This study aims to
investigate the clinicopathological features, diagnosis, treatment, and outcomes of primary gastric ASC.
Methods: The medical records of 13 consecutive patients with primary gastric ASC between January 2010 and July
2014 from a single institutional database were reviewed.
Results: Male predominance was observed (M/F = 10/3) among the patients, and their median age was 62 years
(range: 43 to 79 years). The primary lesions were most often found in the upper third of the stomach, with a
median tumor size of 5 cm (range: 2.25 cm to 10.5 cm). Ten patients underwent radical resections (R0 resection,
76.9%), while three patients had palliative resections (R1/R2 resection, 23.1%). Twelve patients had lymph node
metastasis at the time of surgery. Adenocarcinoma and squamous cell carcinoma components in lymph node were
found in eight and two cases, respectively, while two patients had both squamous cell carcinoma and
adenocarcinoma components. In terms of the TNM staging system, stages IIB, IIIA, IIIB, IIIC, and IV were detected in
2 (15.4%), 2 (15.4%), 1 (7.7%), 5 (38.5%), and 3 (23.1%) patients, respectively. The median follow-up period was
22 months (range: 5 to 52 months); during which, four patients were still alive and eight patients died because of
tumor progression. The 1-, 2-, and 3-year survival rates were 76.9%, 46.2%, and 15.4%, respectively.
Conclusions: Primary gastric ASC has a very poor prognosis, and both squamous cell carcinoma and
adenocarcinoma components have distant metastasis potential.
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Adenosquamous carcinoma (ASC) is a rare entity that
occurs throughout the entire alimentary tract [1-3]. The
incidence of primary gastric ASC is uncommon, ac-
counting for less than 1% of the total gastric carcinomas
worldwide [4,5] and mostly affecting Asians. Primary
gastric ASC exhibits early tumor progression and poorer
prognosis than the typical gastric adenocarcinoma [4].
The biological behavior of ASC is usually determined by
the adenocarcinoma component [6,7]. Patients with* Correspondence: hxwcwk@126.com
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unless otherwise stated.gastric ASC have variable clinical symptoms, some of
which are identical to those of other types of gastric
tumors.
Given the rarity of these carcinomas, most literatures
are based on case reports [2,4,5,7-11]. The histogenesis
of these tumors has been debated considerably, and clin-
ical therapies and prognosis of ASC have not been well
established to date [12]. Therefore, in the current study,
we incorporated the data of 13 consecutive patients with
primary gastric ASC who underwent surgery at a single
medical institution. We investigated the clinicopatholog-
ical features, diagnosis, treatment, and survival outcomes
of these patients to contribute to deeper knowledge on
this tumor and provide additional assistance for ASC
management.his is an Open Access article distributed under the terms of the Creative
ommons.org/licenses/by/4.0), which permits unrestricted use, distribution, and
iginal work is properly credited. The Creative Commons Public Domain
g/publicdomain/zero/1.0/) applies to the data made available in this article,
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Patient selection
Thirteen patients who were surgically treated and patho-
logically diagnosed with primary gastric ASC at the
Department of Gastrointestinal Surgery, West China
Hospital, Sichuan University from January 2010 to July
2014 were retrospectively identified. Contrast-enhanced
computed tomography scan of the chest and abdomen,
electronic gastroscopy, lung function, renal and liver
function, and others were routinely performed preope-
ratively. All surgical samples were reviewed by a senior
pathologist from our institution. ASC diagnosis was
confirmed when the characteristics of coexistence of
squamous cell carcinoma (SC) and adenocarcinoma com-
ponents (AC) were identified, with SC accounting for at
least 20% to 25% [13,14]. Patients diagnosed with non-
gastric ASC having incomplete medical records and did
not attend the follow-up examination were excluded from
this study. The Institutional Review Board and Ethics
Committee of the West China Hospital of Sichuan Uni-
versity informed that an ethical review was not needed for
this retrospective study.Surgery and immunohistochemical examination
All patients underwent laparotomy with general anesthesia;
surgical procedures were performed according to the cri-
teria of the Japanese Gastric Cancer Association [13], in-
cluding subtotal gastrectomy or total gastrectomy and
D2 lymphadenectomy or greater D2 lymphadenectomy.
Operation consent was obtained from each patient who
underwent surgical resection. Two patients underwent
proximal gastrectomy with gastric tube reconstruction.
The specimens for histological examination were fixed in
10% buffered formalin and stained immunohistochemi-
cally for carcinoembryonic antigen (CEA), cytokeratin
(CK) 5/6/7, p63, chromogranin A (CgA), and synapto-
physin (Syn).Data collection and follow-up
The parameters collected from the medical records and
pathological reports included demographic data, clinical
manifestation at the time of diagnosis, hospital stay, sur-
gical data, tumor size and location, pathological data
(Borrmann types, depth of invasion, lymphatic metastasis,
TNM stages, and so on.), immunohistochemical staining,
postoperative tumor recurrence, and so on. Tumor TNM
stages were graded according to the criteria of the Seventh
Edition of the American Joint Committee on Cancer Sta-
ging Manual [15]. Overall survival time was calculated
from the time of surgery to death or until the last follow-
up. Follow-up was conducted through office visit, tele-
phone, or outpatient clinic visit from September 2014 to
October 2014.Results
Patient characteristics
The clinicopathological data of the ASC patients are
summarized in Tables 1 and 2. This entire cohort is
comprised of 10 males and 3 females, with a male-
female ratio of 3.3:1. The ages of the patients ranged
from 43 to 79 years (median: 62 years). A preoperative
biopsy showed ASC in only two patients. The primary
lesions were mostly found in the upper third of stomach,
with a median tumor size of 5 cm (range: 2.25 to
10.5 cm). Borrmann types I, II, and III carcinoma were
observed in 1 (7.7%), 6 (46.2%), and 6 (46.2%) cases, re-
spectively. The clinical symptoms were identical to those
of other types of gastric tumors, with epigastric pain,
dysphagia, and acid regurgitation as the main clinical
manifestations. The mean hospital stay length was 19.3 ±
6.1 days. Two patients (numbers 2 and 5) had type 2 dia-
betes mellitus, while one patient (number 5) was con-
firmed with liver cirrhosis during the operation.
Surgical and adjuvant treatment
All 13 ASC patients were surgically treated through
abdominal approach, including D2 lymphadenectomy or
greater D2 lymphadenectomy. Ten patients underwent
radical resections (R0 resection, 76.9%), while the other
three patients had palliative resections (23.1%), including
multiple liver metastasis (number 11), liver metastasis
with cirrhosis (number 5), and involvement of pancreas/
spleen (number 2). Total, proximal, and distal gastrec-
tomy was conducted in 3, 6, and 4 cases, respectively.
Two patients underwent gastric tube reconstruction
after proximal gastrectomy. In terms of the TNM staging
system, stages IIB, IIIA, IIIB, IIIC, and IV were detected
in 2 (15.4%), 2 (15.4%), 1 (7.7%), 5 (38.5%), and 3 (23.1%)
patients, respectively. Adjuvant therapies were routinely
recommended for patients with palliative resection, and
stage II, III, or IV. Chemotherapy regimens for squamous
carcinoma should be conducted when SC component be-
comes a dominant in tumor tissue. A total of six patients
received adjuvant therapy. Three patients were treated
with chemotherapy of SOX regimen for five cycles (num-
bers 1, 9, and 11), while the other three patients received
FOLFIRI for three cycles (number 5), FOLFOX for seven
cycles (number 4), and Gimeracil and Oteracil Porassium
capsules for four cycles (number 12). Two (numbers 1
and 9) of the six patients also received abdominal radio-
therapy (GTV 60.2GY/28f, CTV 50.4GY/28f).
Pathological and immunohistochemical examination
Table 2 shows the pathological characteristics of the 13
primary gastric ASC patients. ASC was characterized as
a mixture of SC and AC (Figure 1). Most squamous cell
carcinoma components had the characteristics of indi-
vidual cell keratinization, keratin pearl, or intercellular
Table 1 Clinicopathological characteristics and demographical data of 13 patients with primary gastric ASC
Case
number




Operation Postoperative complication Adjuvant therapy
1 M 51 U 2.5*2 II 29 Radical Abdominal infection Yes
2 F 66 M 11*10 III 28 Palliative - No
3 M 63 U 7*6 III 21 Radical - No
4 M 43 L 6*5 II 11 Radical Pulmonary infection Yes
5 M 79 U 7*5 III 27 Palliative Ileus Yes
6 M 62 U 8*4 II 21 Radical - No
7 M 47 L 5*5 II 11 Radical - No
8 F 70 U 4*4 I 18 Radical - No
9 M 63 L 5*5 III 17 Radical - Yes
10 M 73 L 4*3 III 13 Radical Digestive bleeding No
11 M 56 U 6*3 II 16 Palliative - Yes
12 F 50 M 3*3 II 22 Radical - Yes
13 M 61 U 5.5*4 III 17 Radical - No
Abbreviations: ASC adenosquamous carcinoma, M male, F female, U upper third of stomach, M middle third of stomach, L lower third of stomach.
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nohistochemical examination. Both CEA and CK7 were
positive in all AC of tumor or AC of metastatic lymph
node; however, SC with these two antibodies were
weakly positive in one and three cases, respectively. P63
expression was positive in the squamous cell carcinoma
component in six patients but negative in adenocarcin-
oma components. No patient had positive expression of
CgA and Syn. The tumor invaded the visceral periton-
eum (T4a) and adjacent tissues (T4b) in six and three
cases, respectively. A total of 359 lymph nodes were
moved; among which, 106 had metastases. Adenocarcin-
oma and squamous cell carcinoma components in lymph











1 IIIA T4a 2/24 M0 40%
2 IV T4b 4/29 Spleen/pancreas 25%
3 IIIC T4a 16/63 M0 65%
4 IIIB T3 8/32 M0 25%
5 IV T4b 4/27 Liver 35%
6 IIB T3 0/12 M0 40%
7 IIIC T4a 27/32 M0 30%
8 IIIA T4a 2/19 M0 75%
9 IIIC T4a 11/19 M0 60%
10 IIB T2 4/21 M0 20%
11 IV T3 9/29 Liver 35%
12 IIIC T4b 8/24 M0 25%
13 IIIC T4a 11/28 M0 45%
Abbreviations: ASC adenosquamous carcinoma, LN lymph nodes, AC adenocarcinomwhile two patients had both squamous cell carcinoma and
adenocarcinoma components (Figure 2).
Survival outcomes
Follow-up was carried out in all 13 patients, with a me-
dian of 22 months (range: 5 to 52 months). Four patients
were still alive, whereas eight cases died because of
tumor progression. Moreover, one patient (number 13)
died because of chronic respiratory failure. All but two
patients with TNM stages IIIA and IIB experienced
tumor recurrence and/or metastasis, with a median time
of progression of 7 months. The most common metasta-
ses were detected in the liver of five patients, followed







AC Liver (7) Death (26)
AC Peritoneal cavity (0) Death (5)
AC and SC Anastomosis (2) Death (7)
AC Peritoneum (17) Death (31)
AC Liver (0) Alive (15)
Absent Peritoneum (21) Death (34)
AC and SC Lung (13) Death (18)
AC Absent (-) Alive (32)
SC Liver (10) Alive (41)
AC Absent (-) Alive (52)
AC Liver (0) Death (13)
SC Liver (9) Death (22)
AC Peritoneum (5) Death (11)
a components, SC squamous cell carcinoma components.
Figure 1 ASC characterized as a mixture of SC and AC. Both squamous cell carcinoma and adenocarcinoma components were found
(A: hematoxylin-eosin staining, ×200; B: hematoxylin-eosin staining, ×400); Immunohistochemistry of p63 protein that was positive in the squamous
cell carcinoma area (C: ×400), and positive staining for adenocarcinoma cell with CEA (D: ×400).
Figure 2 Squamous cell carcinoma and adenocarcinoma components were found in the lymph node metastasis in the same patient.
Adenocarcinoma component, positive for CK7 (A: ×400); and squamous component, positive for p63 (B: ×400).
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quency ablation. The median overall survival time and
time to progression were 22 and 9 months, respectively.
A trend for better survival was observed in patients
treated with adjuvant therapy (median survival time:
24 months vs. 18 months). The 1-, 2-, and 3-year sur-
vival rates were 76.9%, 46.2%, and 15.4%, respectively.
Given the limited sample size, analysis of the relevant
prognosis factors of ASC was not attempted.Discussion
Adenocarcinoma is the most common malignant tumor
of the stomach; primary gastric ASC is a rare clinical
entity. ASC of the stomach has gained a great deal of in-
terests because of its unsolved histogenesis; its clinico-
pathological and immunohistochemical characteristics
are poorly understood [7,13]. Rolleston and Trevor first
reported on gastric ASC in 1905. Notably, the majority
of patients with ASC were diagnosed at an advanced
stage, with high-grade malignancy and poor prognosis
[2,4]. ASC occurrence is more frequent in the proximal
stomach among middle-aged and aged populations, as
well as among Asian men [1,5,16]. In the current study,
the male to female ratio was 3.3:1. Occurrence is mainly
observed in the upper third of the stomach among pa-
tients with median age of 62 years, which is in agree-
ment with previous reports. The clinical presentations of
gastric ASC can be variable but are basically identical to
those of other types of gastric cancer, and presented
mainly as epigastric pain [4,7].
According to the World Health Organization classifi-
cation, ASC consists of a mixture of adenocarcinoma
and squamous cell carcinoma components. However, the
histogenesis of SC remains controversial. The following
hypotheses have been proposed concerning its most
likely origin [1,4,8,17-19]: 1. Foci of heterotopic squa-
mous epithelia in the gastric mucosa; 2. Stem cell of the
gastric mucosa that differentiated toward both cellular
lines; 3. Metaplastic transformation of an adenocarcin-
oma or benign squamous gastric epithelia; 4. Endothelial
cells differentiated toward squamous elements; and 5.
Collision of an adenocarcinoma and a squamous cell
carcinoma. Currently, the hypothesis that SCs are de-
rived from adenocarcinoma is favored by many scholars.
ASC has one obvious transition area between the two
components and adjoined adenocarcinoma components.
The positive expression of CK7 and CEA in SC from the
available data supports the hypothesis that SC originated
from adenocarcinoma [1,19]. Moreover, SC in ASC may
differentiate into those that resemble pure squamous cell
carcinoma or those with totally different biological be-
haviors [17]. In this study, weak positive expression of
CEA and CK7 in SC were observed with one and threecases, respectively. Hence, more studies are required to
confirm the histogenesis of gastric ASC.
Macroscopically, the majority of ASCs observed are
Borrmann types II and III, whereas types I and IV are
rare [17,20]. Diagnosed ASC is usually accompanied by
distant metastasis, such as peritoneal dissemination,
lymph node metastasis, and liver metastasis [4-6]. As
shown in the present series, the most common site of
metastasis is the liver, followed by peritoneal dissemin-
ation. We also found that both SC and AC have the po-
tential for distant metastasis, similar to those reported in
other publications [1,17]. ASC is usually found deep into
the muscular layer, with more aggressive clinicopatho-
logical characteristics. The findings in this study show
that the tumor invaded the visceral peritoneum (T4a) or
adjacent tissues (T4b) in six and three cases, respect-
ively. Most patients were diagnosed at more advanced
stages. A noteworthy standpoint was raised by Bansal
et al. [7], who considered that the biological behaviors
may be determined by the AC in ASC of the stomach.
Meanwhile, several studies have shown that the biological
behaviors of ASC are usually similar to those of an aggres-
sive adenocarcinoma [6,18,21]. However, a convincing
conclusion cannot be reached based on a case report or
observation with a small number of samples.
No standard treatment for primary gastric ASC has
been established because of its rarity. At present, com-
plete surgical resection to achieve R0, including resetting
the proximity of organs or directly surrounding normal
tissues as necessary, remains the main curative method
for all malignant tumors. Regrettably, the therapeutic
outcomes of ASC are unsatisfactory, and most patients
exhibit a very rapid deteriorating course within a few
months postoperatively [4,7]. Patients who received
adjuvant chemotherapy had better outcomes. S-1 mono-
therapy, cisplatin, fluoropyrimidine, docetaxel, and irino-
tecan reportedly improve survival times, but still with
poor prognosis [1,5,10,22]. Squamous carcinoma is sen-
sitive to radiotherapy; hence, postoperative radiotherapy
can also be used as one of the comprehensive treatments
for ASC. As described previously, patients with cervical
ASC derive relatively better survival benefits from adju-
vant radiotherapy [23,24]. In our study, a trend for better
survival in patients treated with adjuvant therapy was ob-
served (median survival time: 24 months vs. 18 months).
Nevertheless, in an effort to gain confirmation of this find-
ing and establish the standard therapeutic approaches,
more data concerning gastric ASC should be collected.
The prognosis of ASC has been discussed in previous
reports. ASC is more aggressive than pure adenocarcin-
oma. The median survival time of gastric ASC ranges
from 12 to 22 months, and the 5-year survival rate is
10% [1,5]. A similar survival result of esophageal ASC
was reported by Chen et al [14]. Their study showed
Chen et al. World Journal of Surgical Oncology  (2015) 13:136 Page 6 of 6that the median survival time was 21 months, and the 1-,
3-, and 5-year overall survival rates were 67.5%, 29.4%,
and 22.9%, respectively. By contrast, cervical ASC patients
seem to have a relatively better outcome [23]. In the
current study, the median overall survival time and time
to progression were 22 and 9 months, respectively. Several
factors affect the prognosis of tumors, such as TNM stage,
tumor size, site, and surgical margin. A study by Lee et al.
[17] showed that p53 protein over-expression and high
Ki-67 labeling index maybe predictors of poor prognosis.
Given the limited sample size in our study, we did not at-
tempt to analyze the independent prognostic factors re-
garding primary gastric ASC.
Conclusions
Primary gastric ASC is a rare entity with poor prognosis.
Surgical resection is still the gold standard treatment for
primary gastric ASC, although the rate of tumor recur-
rence/metastasis remains high even after radical resection.
Adjuvant therapy (chemotherapy and/or radiotherapy)
can improve survival time. Large-sample investigations
are needed to determine the prognostic factors and find
new therapeutic approaches to achieve better prognosis.
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